These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 17212661

  • 1. Effect of HER-2/neu overexpression on chemoresistance and prognosis in ovarian carcinoma.
    Sasaki N, Kudoh K, Kita T, Tsuda H, Furuya K, Kikuchi Y.
    J Obstet Gynaecol Res; 2007 Feb; 33(1):17-23. PubMed ID: 17212661
    [Abstract] [Full Text] [Related]

  • 2. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.
    Riener EK, Arnold N, Kommoss F, Lauinger S, Pfisterer J.
    Gynecol Oncol; 2004 Oct; 95(1):89-94. PubMed ID: 15385115
    [Abstract] [Full Text] [Related]

  • 3. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma.
    Tanabe H, Nishii H, Sakata A, Suzuki K, Mori Y, Shinozaki H, Watanabe A, Ochiai K, Yasuda M, Tanaka T.
    Gynecol Oncol; 2004 Sep; 94(3):735-9. PubMed ID: 15350366
    [Abstract] [Full Text] [Related]

  • 4. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y, Soslow RA, Marshall DS, Leitao M, Chen B.
    Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
    [Abstract] [Full Text] [Related]

  • 5. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
    Hengstler JG, Lange J, Kett A, Dornhöfer N, Meinert R, Arand M, Knapstein PG, Becker R, Oesch F, Tanner B.
    Cancer Res; 1999 Jul 01; 59(13):3206-14. PubMed ID: 10397267
    [Abstract] [Full Text] [Related]

  • 6. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.
    Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, Nørgaard-Pedersen B, Høgdall CK.
    Cancer; 2003 Jul 01; 98(1):66-73. PubMed ID: 12833457
    [Abstract] [Full Text] [Related]

  • 7. p53 and HER-2/neu overexpression in ovarian borderline tumors.
    Eltabbakh GH, Belinson JL, Kennedy AW, Biscotti CV, Casey G, Tubbs RR.
    Gynecol Oncol; 1997 May 01; 65(2):218-24. PubMed ID: 9159328
    [Abstract] [Full Text] [Related]

  • 8. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
    Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S.
    Cancer; 2005 Oct 01; 104(7):1391-7. PubMed ID: 16116605
    [Abstract] [Full Text] [Related]

  • 9. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
    Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ.
    Oncogene; 1997 Jul 31; 15(5):537-47. PubMed ID: 9247307
    [Abstract] [Full Text] [Related]

  • 10. HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays.
    Mayr D, Kanitz V, Amann G, Engel J, Burges A, Löhrs U, Diebold J.
    Histopathology; 2006 Jan 31; 48(2):149-56. PubMed ID: 16405663
    [Abstract] [Full Text] [Related]

  • 11. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma.
    Kowalski LD, Kanbour AI, Price FV, Finkelstein SD, Christopherson WA, Seski JC, Naus GJ, Burnham JA, Kanbour-Shakir A, Edwards RP.
    Cancer; 1997 Apr 15; 79(8):1587-94. PubMed ID: 9118043
    [Abstract] [Full Text] [Related]

  • 12. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.
    Afify AM, Werness BA, Mark HF.
    Exp Mol Pathol; 1999 Jun 15; 66(2):163-9. PubMed ID: 10409445
    [Abstract] [Full Text] [Related]

  • 13. ErbB-3 predicts survival in ovarian cancer.
    Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, Brulport M, Bauer A, Schiffer IB, Gebhard S, Schmidt M, Steiner E, Sehouli J, Edelmann J, Läuter J, Lessig R, Krishnamurthi K, Ullrich A, Hengstler JG.
    J Clin Oncol; 2006 Sep 10; 24(26):4317-23. PubMed ID: 16896008
    [Abstract] [Full Text] [Related]

  • 14. Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma.
    Koka V, Potti A, Koch M, Fraiman G, Mehdi S, Levitt R.
    Anticancer Res; 2002 Sep 10; 22(3):1593-7. PubMed ID: 12168842
    [Abstract] [Full Text] [Related]

  • 15. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.
    Wang ZR, Liu W, Smith ST, Parrish RS, Young SR.
    Exp Mol Pathol; 1999 Jun 10; 66(2):140-8. PubMed ID: 10409442
    [Abstract] [Full Text] [Related]

  • 16. Clinical significance of Her-2/neu overexpression in uterine serous carcinoma.
    Díaz-Montes TP, Ji H, Smith Sehdev AE, Zahurak ML, Kurman RJ, Armstrong DK, Bristow RE.
    Gynecol Oncol; 2006 Jan 10; 100(1):139-44. PubMed ID: 16182348
    [Abstract] [Full Text] [Related]

  • 17. [Relationship between overexpression of HER-2/neu protein and prognosis in epithelial ovarian cancer].
    Sasaki N, Takano M, Kudou K, Kita T, Kikuchi Y.
    Nihon Rinsho; 2004 Oct 10; 62 Suppl 10():582-6. PubMed ID: 15535312
    [No Abstract] [Full Text] [Related]

  • 18. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.
    Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P.
    Cancer Res; 1990 Jul 01; 50(13):4087-91. PubMed ID: 1972347
    [Abstract] [Full Text] [Related]

  • 19. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study.
    Verri E, Guglielmini P, Puntoni M, Perdelli L, Papadia A, Lorenzi P, Rubagotti A, Ragni N, Boccardo F.
    Oncology; 2005 Jul 01; 68(2-3):154-61. PubMed ID: 16020953
    [Abstract] [Full Text] [Related]

  • 20. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray.
    Giltnane JM, Murren JR, Rimm DL, King BL.
    Histopathology; 2006 Aug 01; 49(2):161-9. PubMed ID: 16879393
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.